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Polymeric stabilizers have received attention in the preparation of nanostructured systems due to their 
ability to enhance formulation stability. Considering this, the objective of this work was to prepare 
poly(ε-caprolactone) nanocapsules using the pullulan as a polymeric stabilizer. The nanocapsules were 
prepared using the interfacial deposition method of preformed polymers and they were characterized 
in terms of pH, average diameter, polydispersity index, zeta potential, beclomethasone dipropionate 
content, encapsulation efficiency, photostability and drug release profiles. The formulations showed 
physicochemical characteristics consistent with nanocarriers for drug delivery such as: average diameter 
lower than 270 nm, polydispersity indexes lower than 0.2, negative zeta potential (-22.7 to -26.3 mV) 
and encapsulation efficiencies close to 100%. In addition, the nanocapsules were able to delay the 
beclomethasone dipropionate photodegradation under UVC radiation and by the dialysis bag diffusion 
technique, the nanocapsules were able to prolong the drug release. Thus, pullulan could be considered 
an interesting excipient to formulate polymeric nanocapsules.
Uniterms: Pullulan. Nanocapsules/diffusion technique. Pullulan/polymeric stabilizer. Biocompatible 
polymers. Beclomethasone dipropionate/nanocapsules.
INTRODUCTION
Nanocapsules are colloidal drug delivery systems 
characterized by a liquid core surrounded by a polymeric 
shell (Mora-Huertas, Fessi, Elaissari, 2010). The core is 
usually composed of liquid lipids but may also present 
a hydrophilic nature. In such nanostructures the drug is 
confined in the core and/or absorbed in the polymeric wall 
(Schaffazick et al., 2003; Kaur et al., 2014).
The nanocapsules preparation requires some raw 
materials including polymer, oil and a combination of 
surfactant/cosurfactant. Biodegradable polyesters such 
as poly(ε-caprolactone), poly(lactide) and poly(lactide-
co-glycolide) are commonly used (Mora-Huertas, Fessi, 
Elaissari, 2010). Regarding the core composition, a variety 
of synthetic and vegetable oils are reported; however, 
medium chain triglycerides are the most employed ones 
due to their low toxicity and high capacity to solubilize 
a wide range of lipophilic drugs (Preetz et al., 2008). 
Oil as well as W/O cosurfactants (common sorbitan 
esters and phospholipids) are also core constituents. 
The main surfactant, in its turn, acts on the particle 
surface and plays a major role as a nanocapsule stabilizer 
agent, being poloxamer 188 and polysorbate 80 more 
commonly employed (Mora-Huertas, Fessi, Elaissari, 
2010). However, such surfactants are known to present 
some incompatibilities with preservatives and other raw 
materials (Allen, 2004). As an alternative, polymeric 
emulsifiers have gained much attention in the preparation 
of dispersed systems due to their capacity to enhance 
formulation stability (Bobin, Michel, Martini, 1999).
Pullulan (figure 1) is an extracellular polysaccharide 
elaborated by the Aureobasidium pullulans fungus. This 
water-soluble biopolymer presents a linear structure 
composed of repeating maltotriose units connected by 
α-1,6-glucosidic bonds (Singh, Saini, Kennedy, 2008). 
Because of its non-toxic, non-carcinogenic and non-
immunogenic properties, the pullulan is being studied for 
pharmaceutical and biomedical applications (Choudhry 
et al., 2012). The pullulan efficacy as an emulsifier was 
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demonstrated in the emulsification of turmeric oleoresin 
(Kshiragar et al., 2007); however, no report on the 
nanoparticles preparation using pullulan as a stabilizer 
agent has been found. On the other hand, hydrophobically 
modified pullulan derivatives were employed to prepare 
nanostructured systems (Hassani, Hendra, Bouchemal, 
2012; Park et al., 2012).
In this way, this work aimed to prepare polymeric 
nanocapsules using pullulan as a stabilizer replacing 
polysorbate 80, a traditional surfactant. Besides this 
change, beclomethasone dipropionate was selected to be 
incorporated in nanocapsules as a drug model due to its 
therapeutic potential, and because it is a corticosteroid 
drug widely used as anti-inflammatory agent in the topical 
treatment of rhinitis and asthma (Brown, George, 1972). 
The developed formulation was characterized in terms of 
pH, particle size and polydispersity index, zeta potential, 
drug content, encapsulation efficiency, photostability and 
in vitro drug release.
MATERIAL AND METHODS
Material
Beclomethasone dipropionate (BD) was obtained 
from Henrifarma (São Paulo, Brazil). Poly(ε-caprolactone) 
(PCL) was supplied by Sigma Aldrich (São Paulo, 
Brazil), sorbitan monooleate (Span 80®) was purchased 
from Delaware (Porto Alegre, Brazil) and pullulan was 
generously gifted by Corn products (São Paulo, Brazil). 
Medium chain triglycerides (MCT) were obtained from 
Brasquim (Porto Alegre, Brazil). HPLC-grade methanol 
was supplied by Tedia (Rio de Janeiro, Brazil). All other 
solvents and reagents were of analytical grade and used 
as received.
Analytical procedures
The experiments were performed on a LC-10A 
HPLC system (Shimadzu, Japan) equipped with a LC-
20AT pump, a UV-VIS SPD-M20A detector, a CBM-20A 
system controller and a Rheodyne valve sample manual 
injector with 50μL loop. The separation was performed 
at room temperature using a RP C18 Phenomenex column 
(250 mm x 4.60 mm, 5 μm; 110 Å) coupled to a C18 guard 
column. The isocratic mobile phase consisted of methanol 
and water (85:15 v/v) at a flow rate of 1.0 mL/min. BD was 
detected at 254 nm with a retention time of 5.9 min. The 
method was linear (r=0.9993) in the concentration range of 
5.0-25.0 µg/mL and precise (RSD<0.96% for repeatability 
and RSD<1.97% for intermediate precision).
Nanocapsule suspensions preparation 
The nanocapsules were prepared in triplicate by 
the interfacial deposition of preformed polymer method 
(Fessi, Puisieux, Devissaguet, 1988). Two phases were 
separately prepared: the organic one consisted of acetone, 
MCT, Span 80®, PCL and BD, the other was an aqueous 
dispersion of pullulan. Both phases were kept under 
magnetic stirring for 60 min. The organic phase was 
maintained at 40 °C while the aqueous phase remained 
at room temperature. In sequence, the organic phase was 
poured in the aqueous one and the resulting mixture was 
FIGURE 1 - Pullulan chemical structure.
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kept under moderate magnetic stirring for 10 min. Then, 
the acetone and part of the water were eliminated under 
reduced pressure to achieve 10 mL of final volume. For 
comparison purposes, the formulations were prepared 
without the drug (blank nanocapsules, NC-B). The 
quali- and quantitative composition of each formulation 
is displayed in Table I, and still considering comparative 
purposes, the nanocapsules were also prepared using 
polysorbate 80 (NC-0.5-P80 and NC-B-P80).
Nanocapsule suspensions physicochemical 
characterization 
After preparation, these formulation characteristics 
were evaluated: pH, particle size, polydispersity index, zeta 
potential, drug content and encapsulation efficiency. The pH 
was directly determined in the samples through a calibrated 
potentiometer (pH 21 model, Hanna Instruments). Particle 
sizes and polydispersity indexes were measured by photon 
correlation spectroscopy (25 °C) (Zetasizer Nanoseries, 
Malvern Instruments). Prior analysis, the samples were 
diluted in ultrapure water (1:500). The Zeta potential was 
evaluated by electrophoretic mobility (Zetasizer Nanoseries, 
Malvern Instruments) after the samples dilution (1:500) in 
10 mM NaCl solution. For the BD content determination, 
an aliquot of nanocapsule suspension was diluted in 
methanol (15 µg/mL) and the sample was kept 10 min 
in an ultrasound, followed by 20 min of centrifugation 
at 3,500 rpm. Lastly, the sample was filtered through a 
regenerated cellulose membrane (0.45 µm) and injected 
into the HPLC system. The encapsulation efficiency was 
evaluated by the ultrafiltration/centrifugation technique 
using Amicon® 10,000 MW devices (Millipore). The 
amount of 200 µL of nanocapsule suspension was placed 
in the device and the centrifugation was carried out at 
2,200 xg for 10 min. The free drug was determined in the 
ultrafiltrate using the HPLC method described above and 
the encapsulation efficiency (EE%) was calculated from the 




The BD photodegradation incorporated into 
nanocapsules (NC-0.5) was studied using an UV artificial 
lamp (Phillips TUV lamp-UVC long life, 30 W). For 
comparison purposes, a BD methanolic solution (BD-MS) 
and a BD methanolic solution covered with aluminum foil 
(dark control) were evaluated as well. The samples were 
placed in plastic cuvettes perfectly stoppered and then 
exposed to UV radiation in a mirrored chamber (1 m x 25 
cm x 25 cm), at a fixed distance. After 5 h of exposure, 300 
µL of the samples were withdrawn, diluted in methanol 
(final BD concentration: 15 μg/mL), and injected into 
the HPLC system according to the previously described 
method. The experiment was performed in triplicate. 
In vitro drug release study
The BD in vitro release from nanocapsules was 
evaluated by the dialysis bag diffusion technique. The 
formulation NC-0.5 and a BD ethanolic solution at 0.5 
mg/mL (BD-ES) were placed in a dialysis bag (MWCO 
10,000, Spectra Por 7) and the system was immersed 
in 150 mL of water with 30% ethanol (37 °C, 50 rpm 
magnetic stirring) to maintain the sink conditions. At 
predetermined intervals, 1 mL of the dissolution medium 
TABLE I - Quali- and quantitative composition of nanocapsule suspensions
NC-0.5 NC-1.0 NC-B NC-0.5-P80 NC-B-P80
Organic phase
Acetone (mL) 27 27 27 27 27
PCL (g) 0.1 0.1 0.1 0.1 0.1
MCT (µL) 330 330 330 330 330
BD (g) 0.005 0.010 - 0.005 -
Span 80 (g) 0.077 0.077 0.077 0.077 0.077
Aqueous phase
Water (mL) 53 53 53 53 53
Pullulan (g) 0.077 0.077 0.077 - -
Polysorbate 80 (g) - - - 0.077 0.077
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was withdrawn and replaced by the same volume of fresh 
medium. The drug released percentage was determined 
by the previous mentioned HPLC method. The mean 
calculated values were obtained from 3 replicates.
Drug release profiles were analyzed by model-
dependent approaches: first order equation (Equation 2) 
and Power law model (Equation 3).
  (2)
  (3)
where Mt is the amount of drug released at time t, M∞ is 
the initial concentration of the drug, k is the kinetic rate 
constant, ft is the ratio of absolute cumulative amount of 
drug released at time t and at infinite time, a is a constant 
incorporating the carrier’s structural and geometric 
characteristics, and n is the release exponent, indicative 
of the drug release mechanism. The fit of the experimental 
data to the models was performed using the Scientist 2.0 
software (Micromath, USA). 
Statistical analysis
The results were expressed as mean ± standard 
deviation. The software used was GraphPad Prism 
Program, version 5. For the variance analysis (ANOVA) 
and post-hoc multiple comparisons. The release profiles 
were analyzed by the two-way ANOVA followed by 
the post hoc Bonferroni test, while the results of the 
photostability study were analyzed by the one-way 
ANOVA, followed by the post hoc Tukey test. In all cases, 
p<0.05 was considered to be statistically significant. 
RESULTS AND DISCUSSION
Polymeric nanocapsules using pullulan as a 
stabilizer agent were prepared by the PCL interfacial 
deposition, a traditional method. Several attempts have 
been made to optimize the pullulan amount; however, 
formulations prepared with concentrations lower than 
0.6% precipitated when the evaporation process happened 
while concentrations upper to 1% resulted in the formation 
of precipitates immediately after preparation. In this way, 
the formulations were prepared with 0.77% of pullulan, the 
same concentration generally employed to prepare PCL 
nanocapsules using polysorbate 80.
After preparation, regardless of the drug presence, 
the nanocapsule suspensions showed a milky appearance 
with an opalescent bluish reflection (Tyndall effect). These 
characteristics are in accordance to other nanocapsule 
formulations reported in literature (Mora-Huertas, Fessi, 
Elaissari, 2010; Schaffazick et al., 2003). In pilot studies, it 
was observed that there was no formation of nanocapsules 
without pullulan. Such fact shows the importance of this 
polysaccharide for the nanocapsule preparation. The 
Pullulan was essential for interfacial tension reduction 
allowing the formation of the nanocapsules shell/core 
structure without precipitation. 
Ta b l e  I I  d i s p l a y s  t h e  p h y s i c o c h e m i c a l 
characteristics of the prepared formulations in comparison 
to those of nanocapsule suspensions prepared employing 
polysorbate 80. The pH determination revealed that the 
samples possess values close to the neutrality, which is 
in accordance to other nanocapsule suspensions prepared 
with PCL (Ourique et al., 2008; Almeida et al., 2009). 
As for the particle sizes evaluation, nanocapsules showed 
an average diameter smaller than 270 nm. Regarding 
the literature, polymeric nanocapsules usually have 
dimensions between 100-500 nm (Quintanar-Guerrero et 
al., 1998). Our findings evidenced that the addition of a 
polymeric emulsifier did not alter the particle sizes when 
compared to nanocapsules prepared with polysorbate 80 
as an emulsifier, and with some reports presented in the 
literature (Ourique et al., 2008; Fontana et al., 2009). 
Furthermore, polydispersity indexes were lower than 0.2 
indicating a narrow size distribution. Concerning the zeta 
potential, nanocapsules showed high negative values, that 
is, higher than formulations prepared with polysorbate 
80 (zeta potential < -12 mV). As higher the value of 
the zeta potential was (in modulus), stabler was the 
nanocapsule suspension due to the repulsive interactions 
among the particles (Hans, Lowman, 2002). In relation 
to the drug content, the formulations NC-0.5 and NC-1.0 
were close to the theoretical value, with encapsulation 
efficiencies greater than 99%. It is relevant to mention 
that in previous trials, PCL nanocapsules prepared with 
polysorbate 80 were able to incorporate only up to 0.5 
mg/mL of drug, evidencing that pullulan enhanced the 
PCL nanocapsules loading capacity. However, the visual 
monitoring of the formulations prepared with pullulan 
revealed that NC-0.5 is stabler than the NC-1.0 because 
this formulation presented precipitates along the storage 
time. For this reason, studies on the photostability and 
drug release profiles were performed only for the NC-0.5 
formulation.
In order to evaluate the PCL ability in nanocapsules 
prepared  wi th  pu l lu lan  to  pro tec t  BD aga ins t 
photodegradation, the NC-0.5 samples were exposed 
to UVC radiation. After 5h of exposure, approximately 
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19% of the initial BD concentration associated to 
nanocapsules remained intact (Figure 2). On the other 
hand, about 5% of the drug in methanolic solution was 
maintained under the same experimental conditions. 
For the dark control, the BD concentration was close 
to 100%, which discards the influence of chamber 
temperature on drug degradation.
Concerning in vitro drug release experiments, Figure 
3 shows that NC-0.5 was able to control BD release in 
comparison to the ethanolic drug solution. In a 24-hour 
period, 99.59% of the free drug was released while 40.48% 
of BD was released from nanocapsules in the same period, 
showing that the nanocarrier prolongs the release.
Mathematical modeling of drug release profiles 
indicated that both samples followed a first order kinetics 
(r>0.99), which means that BD release occurred in a single 
step without a rapid initial release. In relation to the drug 
release mechanism, the release exponent n obtained from 
Power law indicates that the BD release from nanocapsules 
is driven by anomalous transport (n=0.67). According 
to the literature, systems presenting spherical geometry, 
n=0.43 indicates Fickian diffusion, while n≥0.85 is related 
to case II transport (Peppas, 1985). Values between these 
limits suggest anomalous transport, i.e., the drug release 
initially depends on the polymer relaxation followed by 
Fickian diffusion (Dey et al., 2009).
CONCLUSION
The use of pullulan as a stabilizer agent for 
polymeric nanocapsules is reported for the first time. 
The prepared formulations showed compatible features 
with other nanostructured systems. The results of zeta 
potential and drug content indicated that the pullulan is 
an advantageous stabilizer in comparison to polysorbate 
80. The photostability as well as the in vitro drug release 
profiles suggest that nanocapsules prepared with pullulan 
can be considered promising drug carriers.
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TABLE II - Nanocapsules physicochemical characteristics







NC-B - 6.6 ± 0.2 242 ± 11 0.18 ± 0.01 -26.3 ± 4.6
NC-0.5 0.49 ± 0.01 6.2 ± 0.2 270 ± 2 0.19 ± 0.02 -22.7 ± 1.4
NC-1.0 0.99 ± 0.01 6.7 ± 0.4 269 ± 2 0.20 ± 0.01 -23.1 ± 0.7
NC-0.5 P80 0.50 ± 0.02 6.9 ± 0.3 218 ± 18 0.14 ± 0.07 -11.1 ± 3.4
NC-B-P80 - 6.5 ± 0.1 291 ± 65 0.22 ± 0.03 -12.3 ± 8.6
FIGURE 3 - In vitro beclomethasone dipropionate release 
profiles from nanocapsules (NC-0.5) and ethanolic solution 
(BD-ES) through the dialysis bag method (n=3).
FIGURE 2 - Nanocapsules beclomethasone dipropionate content 
(NC-0.5), methanolic solution (BD-MS) and dark control under 
UVC radiation. 
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